What Has Been the Growth of the Chronic Liver Diseases Therapeutics Market So Far?
The chronic liver diseases therapeutics market has seen considerable growth due to a variety of factors.
• The market size for therapeutics related to chronic liver disease has seen a sharp increase in recent times. Projected growth for this market is from $14.38 billion in 2024 to a substantial $15.92 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.7%.
The factors contributing to such growth during the historical period include escalating incidence of viral hepatitis, rising obesity rates, aging population, increased health-awareness specifically towards liver health, and enhanced patient access to medical treatment.
How Will the Chronic Liver Diseases Therapeutics Market Size?
The chronic liver diseases therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• Predictions indicate a swift expansion in the chronic liver disease therapeutics market size in the coming years. It is thought to reach a value of $23.83 billion in the year 2029, growing at a compound annual growth rate (CAGR) of 10.6%.
Factors contributing to this projected growth include an increase in attention paid to personalized medicine, a wider pipeline of novel therapies, the extension of telemedicine and digital health solutions, and increased demand for liver disease prevention programs, as well as a rise in viral hepatitis cases. Major tendencies in this market are expected to be the use of artificial intelligence in diagnostics, the growth of biologics and gene therapies, development of non-invasive treatment methods, combined therapies, and the extension of care models that focus on the patient.
Which Drivers Are Accelerating Growth In The Chronic Liver Diseases Therapeutics Market?
The upsurge in alcohol intake is anticipated to boost the expansion of the chronic liver disease therapeutics market. Alcohol intake refers to the consumption of drinks containing ethanol, from moderate to excessive levels, which can potentially impact health. Factors such as societal acceptance, increased income, and global accessibility are contributing to the rise in alcohol consumption. Therapeutics for chronic liver disease are used to manage liver damage caused by excessive alcohol intake, decelerating the progression of disease and enhancing liver functioning. As an example, the First Citizens Bank, a US-based financial entity, recorded a rise of 1.2% in direct-to-consumer (DTC) wine case sales in 2023 compared to 2022 in June 2024. Similarly, Kirin Holdings Company Limited, a beverage company based in Japan, reported in December 2023 that approximately 192.1 million kiloliters of beer were drunk in 2022, marking a 2.9% rise from the prior year. Consequently, the escalating alcohol intake is fueling the expansion of the chronic liver disease therapeutics market.
What Key Areas Define The Segmentation Of The Global Chronic Liver Diseases Therapeutics Market?
The chronic liver diseases therapeutics market covered in this report is segmented –
1) By Treatment Type: Antiviral Drugs, Immunosuppressants Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy
2) By Disease Type: Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders
3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues, Interferons, Direct-Acting Antivirals
2) By Immunosuppressants: Calcineurin Inhibitors, mTOR Inhibitors, Purine Synthesis Inhibitors
3) By Vaccines: Hepatitis A Vaccine, Hepatitis B Vaccine, Combination Hepatitis Vaccines
4) By Immunoglobulins: Hepatitis B Immune Globulin, Intravenous Immunoglobulin
5) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone
6) By Targeted Therapy: Tyrosine Kinase Inhibitors, Monoclonal Antibodies
7) By Chemotherapy: Systemic Chemotherapy, Transarterial Chemoembolization Agents
Pre-Book The Chronic Liver Diseases Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Chronic Liver Diseases Therapeutics Market?
Key players in the therapeutics market for chronic liver diseases are concentrating on pioneering advanced innovations, like RNA therapies that target specific genetic and molecular mechanisms to provide more effective and personalized treatment methods. RNA therapies are cutting-edge health treatments utilizing RNA molecules to regulate gene expression or protein synthesis with a goal to cure or prevent diseases via targeting distinct genetic mechanisms. For example, in May 2022, Ochre Bio, a biotech firm based in the UK, introduced its groundbreaking 'Liver ICU' research facility at BioLabs@NYULangone, a biopharma incubator in New York City. This modern site evaluates the efficacy of next-generation RNA therapeutics by utilizing entire human livers maintained on perfusion machines. The facility capitalizes on discarded donor livers for research purposes, striving to speed up drug development schedules and enhance the accuracy of liver treatment studies by mimicking human physiological conditions.
Who Are the Key Players In The Chronic Liver Diseases Therapeutics Market?
Major companies operating in the chronic liver diseases therapeutics market are:
• F. Hoffmann-La Roche AG
• Merck & Co. Inc.
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Novo Nordisk A/S
• Dr. Reddy's Laboratories Ltd.
• Vir Biotechnology Inc.
• Alnylam Pharmaceuticals Inc.
• Indian Immunologicals Limited
• Intercept Pharmaceuticals Inc.
• Viking Therapeutics Inc.
• Ascletis Pharma Inc.
• Ochre Bio Limited
• Tiziana Life Sciences Ltd.
• Antios Therapeutics Inc.
What Is The Most Dominant Region In The Chronic Liver Diseases Therapeutics Market?
North America was the largest region in the chronic liver diseases therapeutics market in 2024. The regions covered in the chronic liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
